HRV Pharma, a global asset-light pharmaceutical platform, is investing approximately Rs. 150 crore to expand its capabilities in two high-value and supply-constrained segments—synthetic peptides and high-potency oncology APIs.

The investments mark the next phase of HRV Pharma’s asset-light business model, with the company seeking to secure dedicated manufacturing capacity, strengthen its portfolio of complex molecules and accelerate access to regulated international markets.

As part of the expansion, HRV Pharma is committing Rs. 40–50 crore towards a dedicated custom peptide capacity programme through a strategic capacity underwriting arrangement. 

The initiative will establish dedicated cGMP peptide manufacturing capacity focused on commercial-stage and new-to-generic synthetic peptides across multiple therapeutic areas.

The capacities are currently being scaled and are expected to be ready within the next six to eight months. HRV Pharma will retain ownership of regulatory assets, product intellectual property and global commercialisation rights under the arrangement. 

The company estimates the total addressable market opportunity for the peptide portfolio at more than US$2 billion.

In a parallel move, HRV Pharma is establishing a strategic joint venture focused on high-potency oncology APIs and specialised pharmaceutical molecules, with an investment commitment of approximately Rs. 100 crore. 

The platform will build capabilities for developing and commercialising high-potency APIs, initially targeting oncology and other niche therapeutic segments where manufacturing capabilities are highly specialised.

The company plans to develop 20–30 oncology and high-potency APIs in phases, beginning with research and development capabilities and regulatory filings, followed by dedicated commercial-scale manufacturing capabilities.

The latest investments build on HRV Pharma’s seven-year-old virtual pharmaceutical platform, which combines regulatory ownership, global customer relationships and a network of certified cGMP manufacturing partners. 

With the new initiatives, the company aims to move beyond its traditional role of orchestrating existing manufacturing capacity towards underwriting specialised capacity in segments where regulated-market capabilities remain limited.

HRV Pharma said its model will continue to focus on controlling key value drivers such as product selection, regulatory filings, intellectual property and global commercialisation, while working with experienced manufacturing partners.

Hari Kiran Chereddi, Founder, Managing Director and CEO, HRV Pharma, said, “The pharmaceutical industry is evolving towards models where regulatory ownership, specialised capabilities, and market access are becoming increasingly important drivers of value creation. At HRV, our focus has always been on identifying areas where the industry requires specialised capabilities and building scalable solutions around them,” Chereddi said.